Premium
Nasal corticosteroids for children with snoring
Author(s) -
Alexopoulos Emmanouel I.,
Kaditis Athanasios G.,
Kalampouka Efthimia,
Kostadima Eleni,
Angelopoulos Nikiforos V.,
Mikraki Vasiliki,
Skenteris Nikolaos,
Gourgoulianis Konstantinos
Publication year - 2004
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.20079
Subject(s) - medicine , polysomnography , apnea , anesthesia , budesonide , hypopnea , sleep apnea , apnea–hypopnea index , inhalation
Nasal corticosteroids improve polysomnography indices but not symptoms in children with mild to moderate sleep‐disordered breathing. We hypothesized that administration of nasal corticosteroids for 4 weeks to snoring children with only mild elevation in their apnea‐hypopnea index would improve both polysomnography findings and symptoms of sleep‐disordered breathing. Budesonide 50 mcg per nostril twice daily was administered for 4 weeks to children (2–14 years old) with habitual snoring and an apnea‐hypopnea index of 1–10 episodes/hr. Subjects were evaluated before treatment and at 2 weeks and 9 months after its completion. Primary outcome variables were changes in apnea‐hypopnea index and symptom score. Twenty‐seven children were studied. At 2 weeks, the mean apnea‐hypopnea index decreased from 5.2 (±2.2) episodes/hr to 3.2 (±1.5) episodes/hr, and median oxygen desaturation of hemoglobin index fell from 3.1 (0.4–8.2) to 1.9 (0.2–5.4) ( P < 0.0001). Mean symptom score was 1.33 (±2.11) at baseline, and decreased to −0.008 (±2.24) at 2 weeks after treatment and to −1.08 (±1.75) at 9 months after treatment ( P < 0.05). Four weeks of nasal budesonide improved both polysomnography findings and symptoms in children with mild sleep‐disordered breathing. The clinical effect is maintained for several months after treatment. Pediatr Pulmonol. 2004; 38:161–167. © 2004 Wiley‐Liss, Inc.